Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Gastroenterology. 2018 Oct;155(4):1090-1097.e1. doi: 10.1053/j.gastro.2018.06.056. Epub 2018 Sep 5.
BACKGROUND & AIMS: There is no effective treatment for aspirin-induced small bowel ulcer bleeding. We performed a double-blind, randomized, placebo-controlled trial to determine whether misoprostol can heal small bowel ulcers in patients with small bowel bleeding who require continuous aspirin therapy.
We performed a prospective study of 84 aspirin users with small bowel bleeding who required continued aspirin therapy in Hong Kong and Japan. Patients with small bowel ulcers or multiple erosions, detected by capsule endoscopy, were randomly assigned to groups that received either misoprostol (200 μg, 4 times daily; n = 42) or placebo (n = 42) for 8 weeks. All patients continued taking aspirin (100 mg, once daily). The primary end point was complete ulcer healing at follow-up capsule endoscopy. Secondary end points included changes in hemoglobin level and number of ulcer/erosions from baseline.
Complete healing of small bowel ulcers was observed in 12 patients in the misoprostol group (28.6%; 95% CI, 14.9%-42.2%) and 4 patients in the placebo group (9.5%; 95% CI, 0.6%-18.4%), for a difference in proportion of 19.0% (95% CI, 2.8%-35.3%; P = .026). The misoprostol group had a significantly greater mean increase in hemoglobin than the placebo group (mean difference, 0.70 mg/dL; 95% CI, 0.05-1.36; P = .035). The reduction in medium number of ulcers or erosions was significantly greater in the misoprostol group (from 6.5 [range, 1-85] to 2 [range, 0-25]) than in the placebo group (from 7 [range, 1-29] to 4 [range, 0-19] (P = .005).
In a double-blind, randomized, placebo-controlled trial, we found misoprostol to be superior to placebo in promoting healing of small bowel ulcers among aspirin users complicated by small bowel ulcer bleeding who require continuous aspirin therapy. However, use of misoprostol alone would provide only limited protection against aspirin on the small bowel. ClinicalTrials.gov ID NCT01998776.
目前尚无有效治疗阿司匹林诱导的小肠溃疡出血的方法。我们进行了一项双盲、随机、安慰剂对照试验,旨在确定米索前列醇是否可以治愈需要持续阿司匹林治疗的小肠出血患者的小肠溃疡。
我们前瞻性研究了 84 例因小肠出血而需要继续服用阿司匹林的香港和日本阿司匹林使用者。通过胶囊内镜检查发现小肠溃疡或多发性糜烂的患者,随机分为接受米索前列醇(200μg,每日 4 次;n=42)或安慰剂(n=42)治疗 8 周的两组。所有患者继续服用阿司匹林(100mg,每日 1 次)。主要终点是随访胶囊内镜检查时完全愈合的溃疡。次要终点包括血红蛋白水平和溃疡/糜烂数量的变化。
米索前列醇组 12 例(28.6%;95%可信区间,14.9%-42.2%)和安慰剂组 4 例(9.5%;95%可信区间,0.6%-18.4%)患者的小肠溃疡完全愈合,比例差异为 19.0%(95%可信区间,2.8%-35.3%;P=0.026)。米索前列醇组血红蛋白平均升高幅度明显大于安慰剂组(平均差异,0.70mg/dL;95%可信区间,0.05-1.36;P=0.035)。米索前列醇组溃疡或糜烂数量中位数减少幅度明显大于安慰剂组(从 6.5[范围,1-85]降至 2[范围,0-25])(P=0.005)。
在一项双盲、随机、安慰剂对照试验中,我们发现米索前列醇在促进需要持续阿司匹林治疗的阿司匹林相关小肠溃疡出血患者的小肠溃疡愈合方面优于安慰剂。然而,单独使用米索前列醇只能对小肠提供有限的阿司匹林保护。临床试验.gov 注册号 NCT01998776。